Moreover, in vitro TIGIT blockade improves the anti-tumor effect of Trastuzumab (a recombinant humanized anti-HER2 monoclonal antibody used in HER2+ breast cancers), which partially relies on NK cell-mediated ADCC [105]. Here, ERBB2 is linked to neoplasm.